SymBio Pharmaceuticals Limited
Stock Price Chart
2026/09/22 UpdatedPrice Trend
2026/09/22 UpdatedPrice & Trading Details
2026/09/22 UpdatedPRICE
TRADING
Earnings Calendar
Updated 2026/09/01Shareholder Composition
Updated 2026/09/01Financial Performance
2026/09/20 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥10,008M | ¥5,590M | ¥2,453M | ¥1,308M |
| Gross Profit | ¥7,600M | ¥4,411M | ¥1,873M | ¥947M |
| Operating Income | ¥1,964M | -¥812M | -¥3,877M | -¥4,441M |
| Pretax Income | ¥1,964M | -¥812M | -¥3,807M | -¥4,709M |
| Net Income | ¥1,179M | -¥1,963M | -¥3,833M | -¥4,776M |
| EPS | ¥29.77 | -¥49.19 | -¥85.00 | -¥95.12 |
| Operating Margin | 19.62% | -14.52% | -158.06% | -339.59% |
| Balance Sheet | ||||
| Total Assets | ¥10,433M | ¥8,170M | ¥4,968M | ¥3,867M |
| Total Equity | ¥8,506M | ¥7,210M | ¥4,198M | ¥1,272M |
| Total Liabilities | ¥1,927M | ¥960M | ¥771M | ¥2,595M |
| Cash | ¥6,283M | ¥6,517M | ¥3,964M | ¥2,884M |
| Interest-bearing Debt | - | - | ¥0M | ¥1,983M |
| Equity Ratio | 81.53% | 88.25% | 84.49% | 32.89% |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 1.56 |
| Cash Flow | ||||
| Operating CF | ¥1,614M | -¥195M | -¥3,417M | -¥4,576M |
| Investing CF | -¥47M | -¥377M | -¥4M | -¥76M |
| Financing CF | ¥628M | ¥680M | ¥708M | ¥3,622M |
| Free CF | ¥1,567M | -¥427M | -¥3,463M | -¥4,658M |
| Efficiency | ||||
| ROE | 13.86% | -27.22% | -91.33% | -375.48% |
| ROA | 11.30% | -24.02% | -77.16% | -123.50% |
Latest IR Information
-
Notice on the Completion of Payment for the 2nd Unsecured Ordinary Bond (Private Placement)
Total amount of the 2nd unsecured ordinary bond (private placement) issued and paid in is 100,000,000 yen. Maturity date is September 3, 2029, interest rate 0%, late surcharge 20%. Issuer is EVO FUND, with related transactions involving new share subscription...
Read more -
Notice regarding the completion of the acquisition and cancellation of the 58th, 66th and 67th stock acquisition rights, and the payment of the issue price for the 70th and 71st stock acquisition rights (with exercise price adjustment clause) issued to a third party
Acquisition and cancellation of stock acquisition rights completed; allocation of the 70th and 71st stock acquisition rights to EVO FUND. Total issue amount: 2,880,000 yen; potential shares: 96,000,000 shares; exercise price adjustment clause; exercise period: 2026/09/03–2029/09/03. Estimated funds raised: 6,768,880,000...
Read more -
Notice on the Monthly Exercise Status of the 58th and 66th Stock Acquisition Rights Issued by Third-Party Allotment (With Exercise Price Adjustment Clause)
Public disclosure of the monthly exercise status for the 58th and 66th stock acquisition rights. In the target month, exercises were 0 shares; unexercised rights are 120,510 shares for the 66th and 20,000 shares for the 58th. In addition, disclosures...
Read more -
Unsecured Bond Facility Agreement and Issuance of the Second Unsecured Ordinary Bond (Private Placement) and Third-Party Allotment of the 70th and 71st Warrants and Conclusion of the Buyback Agreement
Setting up a unsecured bond facility of up to 5 billion yen with EVO FUND as the, issuer; issuing the Second Unsecured Ordinary Bond. Warrants for the 70th and 71st will be allocated to EVO FUND, with a revised exercise...
Read more -
SymBio Pharmaceuticals Co., Ltd. 2026 Fiscal Year December Quarter 2 Interim Financial Summary
For the interim period of the 2026 fiscal year, net sales were 469 million yen, operating loss was 3,635 million yen, ordinary loss was 3,608 million yen, and net loss attributable to owners of the parent was 3,619 million yen....
Read more
Latest News (5 items)
Company Information
About
SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.
